Latest news with #InflammatoryBowelDisease
News18
2 days ago
- Health
- News18
From Constipation To Microbiome Imbalance: How Dehydration Impairs Gut Health
When you are dehydrated and when your water intake is less than the adequate level, a range of gut-related issues can emerge. Water plays a vital role in nearly every physiological process, and gut health is no exception. From digestion and nutrient absorption to waste elimination, your digestive system relies heavily on adequate hydration. When water intake falls short, a range of gut-related issues can emerge, potentially compromising your overall well-being. Dr. Gyan Ranjan Rout, Consultant, Medical Gastroenterologist, Manipal Hospital, Bhubaneswar, shares how dehydration can have an impact on your gut health. 1. Constipation: The Most Immediate Red Flag One of the most common and visible effects of dehydration is constipation. Water helps keep stools soft and easy to pass. Dr Rout says, 'When the body is dehydrated, it draws water from the colon to maintain other essential functions. This results in dry, hard stool that moves sluggishly through the intestines, often causing abdominal discomfort. Chronic constipation can lead to bloating, gas, and in more severe cases, complications like hemorrhoids or anal fissures due to excessive straining." 2. Impaired Nutrient Absorption Beyond constipation, dehydration can negatively impact how the gut absorbs nutrients. Water is essential for maintaining the integrity of the mucosal lining of the intestines, crucial for absorbing vitamins, minerals, and electrolytes. Dr Rout explains, 'When this lining is compromised due to insufficient hydration, the body's ability to maintain nutrient balance falters. Over time, this can result in deficiencies, fatigue, and a weakened immune response." 3. Gut Microbiome Imbalance A well-hydrated body supports a healthy gut microbiota – the diverse ecosystem of bacteria that influences digestion, immunity, mood, and more. Dehydration may disturb this balance, allowing harmful bacteria to thrive and increasing the risk of inflammation. Dr Rout notes, 'This imbalance can worsen conditions like Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD), and even in milder cases, lead to irregular bowel movements and general digestive discomfort." 4. Sluggish Digestion and Enzyme Production Water is essential for producing saliva and digestive enzymes that begin the breakdown of food. It also helps move food efficiently through the digestive tract. Without sufficient fluid intake, this process slows down. The result? Increased chances of indigestion, nausea, and heartburn. Consistent hydration is key to keeping your digestive system functioning smoothly. Drinking enough water throughout the day not only helps prevent constipation but also supports nutrient absorption, a balanced microbiome, and overall digestive comfort. view comments First Published: July 21, 2025, 17:25 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Cision Canada
15-07-2025
- Health
- Cision Canada
Health Canada Approves Lilly's Omvoh® (mirikizumab) for Crohn's Disease; New Citrate-Free Formulation Français
Omvoh ® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn's disease (CD) In VIVID-1, Omvoh ® showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately to severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. 3 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, which contains the same active ingredients as the original Omvoh ®. TORONTO, July 15, 2025 /CNW/ - Eli Lilly Canada Inc. (Lilly Canada) announced today that Health Canada has approved Omvoh ® (mirikizumab) for CD, which will soon be available to patients in Canada. Omvoh ® is an interleukin-23p19 antagonist for the treatment of adult patients with moderately to severely active CD who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment. 1 Health Canada has also approved a new citrate-free formulation of Omvoh ® for subcutaneous injection, for the existing UC indication, as well as the new CD indication. "We are pleased to see that Omvoh ® will now be able to provide people living with moderately to severely active CD an effective and safe option for treatment," said Mathilde Merlet, President and General Manager of Lilly Canada. "With this additional indication, we are reinforcing our commitment to helping more of the IBD community. Additionally, we are proud to be able to introduce a new citrate-free formulation, which we hope will improve the patient experience, while offering the same quality, efficacy, and safety that patients are accustomed to." The authorization of Omvoh ® for CD was based on results from the VIVID-1 clinical study, which included over 1,000 adults. In VIVID-1, mirikizumab showed statistically significant and clinically meaningful efficacy across multiple endpoints compared with placebo in patients with moderately-to-severely active CD, meeting the coprimary composite endpoints and all major secondary endpoints. The coprimary composite endpoints included patient-reported outcome (PRO) clinical response at week 12 and endoscopic response at week 52 (endoscopic response-composite), and PRO clinical response at week 12 and Crohn's Disease Activity Index (CDAI) clinical remission at week 52 (CDAI clinical remission-composite). Endoscopic response-composite was reached in 220 (38%) of 579 patients on mirikizumab versus 18 (9%) of 199 patients on placebo; CDAI clinical remission-composite was reached in 263 (45%) of 579 patients on mirikizumab versus 39 (20%) of 199 patients on placebo. Statistical significance was also observed in subgroups with and without failure to biological therapies for coprimary endpoints and most major secondary endpoints. 3 The Community Reacts: Sylvain Chiasson, Interim President & CEO of Crohn's and Colitis Canada: "Crohn's and Colitis Canada always welcomes new treatments for people with CD in Canada. CD is a chronic autoimmune disease where the immune system attacks the gastrointestinal system. CD is a complex disease that is debilitating, leads to hospitalizations and surgeries, and has a tremendous impact on the quality of life for the approximately 162,000 Canadians living with this disease. Because of the disease's complexity, not all people with CD respond in the same way to the available treatments. So, it is welcome news for Crohn's and Colitis Canada when there is a new therapy available for people with CD." Gail Attara, Chief Executive Officer of the Gastrointestinal Society ( "We are so pleased to learn that Health Canada has approved a CD indication for Omvoh (mirikizumab). Compared to other inflammatory conditions, CD has very few medications, so the introduction of Omvoh's expanded use as a new option is excellent news for the IBD community." Dr. John Marshall, Professor of Medicine, and Director of the Division of Gastroenterology at McMaster University: "It is exciting to see a new and highly effective therapy being made available for people living with CD. Clinical trials have shown mirikizumab to be both safe and effective, and this will be an appealing treatment option for patients who are new to biologic therapies, or those who have not responded adequately to previous advanced therapies." About the VIVID-1 Clinical Trial Program VIVID-1 was a Phase 3, randomized, double-blind, treat-through study that evaluated the safety and efficacy of mirikizumab compared with placebo and an active control (ustekinumab) in adults with moderately to severely active CD. Patients randomized to mirikizumab were administered 900 mg of mirikizumab intravenously every four weeks from Weeks 0-8, then 300 mg subcutaneously every four weeks from Weeks 12-52. In this study, 49% of patients treated with mirikizumab or placebo had experienced a prior biologic failure. 2 The overall safety profile of mirikizumab in patients with moderately to severely active CD was consistent with the known safety profile in patients with UC. The frequency of serious adverse events was greater in placebo than mirikizumab. The most common adverse events were upper respiratory tract infections, injection site reactions, headache, and rash. 1 About Omvoh ® Omvoh ® (mirikizumab) is an interleukin-23p19 (IL-23) antagonist indicated for the treatment of moderately to severely active UC and CD in adults. Omvoh ® selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to overactivation of the IL-23 pathway plays a critical role in the pathogenesis of CD, a chronic, IBD associated with progressive bowel damage, disability and decreased health-related quality of life. For more information about Omvoh ®, please refer to the product monograph on About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. Lilly has been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Lilly's Canadian Affiliate, Eli Lilly Canada Inc. was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially available insulin. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more about Lilly Canada, visit or follow us on LinkedIn. Omvoh ® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Al Etihad
03-07-2025
- Health
- Al Etihad
For first time outside United States, Abu Dhabi approves, accelerates access to innovative treatment for IBD
3 July 2025 20:46 ABU DHABI (WAM)On the side-lines of Abu Dhabi's participation at BIO International Convention in Boston, USA, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, in collaboration with Johnson & Johnson (J&J) and Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the UAE for serious and complex care and a subsidiary of the PureHealth group, have successfully enabled expedited access to Tremfya®, a next-generation biologic medication for patients with Inflammatory Bowel Disease (IBD).This strategic partnership marks the first availability of the treatment outside the United States, reinforcing Abu Dhabi's position as a pioneering destination for healthcare innovation and advanced, patient-focused the recent US FDA approval for ulcerative colitis and Crohn's disease and European Commission's approval for Crohn's disease, the DoH led efforts to accelerate local access through this three-way the supervision of the Department of Health – Abu Dhabi (DoH), SSMC's specialised IBD Centre will now administer Tremfya® to patients, offering a new standard of care for those living with chronic IBD Executive Director of the Health Life Sciences Sector at the DoH, Dr. Asma Al Mannaei, said, 'This collaboration exemplifies Abu Dhabi's commitment to pioneering healthcare advancements that transform patient care. By being the first outside the United States to offer Tremfya® for both Crohn's disease and ulcerative colitis, we are reinforcing our dedication to strategic partnerships and innovative treatments that address chronic diseases. Abu Dhabi continues to position itself as a leader in health innovation by enhancing patient outcomes and bringing novel treatment solutions to the region.'Consultant Gastroenterologist and Director of the IBD Service at Sheikh Shakhbout Medical City, Dr. Mohammed Nabil Quraishi, commented on this milestone, "At SSMC, our goal is to be at the forefront of medical innovation, but the real success story is the immediate impact this has on our patients. Being the first in the country to administer this novel therapy was a vital first step, but to have already started treatment for 15 patients in under two months of its launch demonstrates the tangible, widespread benefit we can deliver. This rapid adoption and scale are a direct result of our high-volume tertiary care service, allowing our expert team to translate groundbreaking medical science into clinical practice without delay. We are not just treating IBD; we are defining a new, higher standard of care for the region."Managing Director at Johnson & Johnson Innovative Medicine, Gulf, Pedro Matos Rosa, said, 'We are honoured to collaborate with Department of Health – Abu Dhabi, and SSMC to facilitate fast access to innovative solution for IBD patients in the Emirate. This partnership reflects our commitment to expanding innovative solutions that can make a meaningful difference in IBD patients' lives.'The first patient in Abu Dhabi to receive Tremfya experienced notable improvement, with symptoms significantly declining despite longstanding treatment-resistant Crohn's disease. Although Tremfya's real world use for Crohn's is recent, clinical trial results demonstrate that it enhances patient outcomes and supports long-term treatment is a biologic therapy that targets key inflammatory pathways involved in IBD, offering patients a novel treatment option that is both precise and highly treatment is designed to help patients achieve clinical remission and reduce disease symptoms. It is the first and only fully human selective interleukin (IL)-23 inhibitor with a dual inhibition mechanism targeting both IL-23 and CD64. It is now approved for adults with moderately to severely active ulcerative colitis and for the treatment of adults with moderately to severely active Crohn's disease as the first IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options for the treatment of these including Crohn's disease and ulcerative colitis, is a chronic inflammatory condition causing symptoms such as abdominal pain, diarrhoea, fatigue, and weight loss. Its incidence is rising in the region. The age-standardised incidence rate (ASIR) of IBD in the Middle East and North Africa (MENA) region increased from 2.9 per 100,000 in 1990 to 3.7 per 100,000 by 2019, representing an increase of approximately 30% over three IBD Centre distinguishes itself by its multidisciplinary team of internationally trained experts, encompassing specialists from gastroenterology, surgery, nutrition, nursing, psychology, and pharmacy – a comprehensive approach unique to few centres across the collaborative team utilises state-of-the-art facilities, including advanced diagnostic tools and a dedicated infusion suite. The integrated approach contributes to excellent clinical outcomes, with the majority of the patients achieving and maintaining rapid disease control. Additionally, SSMC IBD Centre, provides access to the latest treatments through active research programmes and clinical trials, and offers extensive patient education and support services, including a dedicated helpline and mental wellness support
Time of India
02-07-2025
- Health
- Time of India
New post and PG course at SAT hosp get Cabinet nod
T'puram: State cabinet has given its approval to establish a professor postition, enabling the commencement of a PG course in the paediatric gastroenterology unit at SAT Hospital. Tired of too many ads? go ad free now This position is part of the expansion of the existing unit into a full-fledged paediatric gastroenterology department. A state-of-the-art endoscopy machine, costing Rs 93 lakh, will soon be installed at SAT. The new department aims to provide modern and quality treatment for gastrointestinal diseases. This is the sixth such department in the country and the first in the state within the govt sector. The PG course will be the fifth of its kind in the country. The course is expected to produce more specialist doctors in this field. In 2021, a paediatric gastroenterology unit was established at SAT Hospital with excellent facilities. The decision to expand its services into a dedicated department was made in response to the increasing prevalence of gastrointestinal issues in children. The goal is to provide comprehensive, modern and effective treatment for all digestive disorders in children, from newborns to adolescents. Since its inception, over 27,000 children have received treatment at SAT Hospital. The department treats gastrointestinal, liver, gallbladder and pancreas-related diseases in children. It offers specialized care for conditions such as abdominal pain, chronic diarrhoea, constipation, vomiting, feeding difficulties, acid reflux, food allergies, growth issues, liver diseases and IBD (Inflammatory Bowel Disease). The department is staffed by a multidisciplinary team of experienced doctors and nurses, utilising the latest technology.
Medscape
23-06-2025
- Health
- Medscape
ACG Updates Guidance on Crohn's Disease Management
The American College of Gastroenterology (ACG) has issued updated guidance on the management of Crohn's disease (CD) that reflects the surge in development of therapeutic options available since 2018, when the last guideline was published. These newer treatment options include interleukin-23 (IL-23) blockers risankizumab, mirikizumab, and guselkumab; the anti-IL-12/23 agent ustekinumab; the JAK inhibitor upadacitinib; and the anti-integrin vedolizumab. The intent of the guideline is to suggest 'preferable approaches' to CD management established through 'interpretation and collation of scientifically valid research, derived from extensive review of published literature,' said the writing group, led by Gary Lichtenstein, MD, director, Inflammatory Bowel Disease Center, Hospital of the University of Pennsylvania, Philadelphia. When exercising clinical judgment, the authors advise healthcare providers to 'incorporate this guideline along with patient's needs, desires, and their values to care for patients fully and appropriately with CD.' The guideline is intended to be 'flexible, not necessarily indicating the only acceptable approach,' and shared decision-making with the patient is advised, they stressed. The 40-page guideline was published online earlier this month in American Journal of Gastroenterology, along with a one-page visual highlights summary . From Diagnosis to Surgery The incidence of CD has steadily increased over the past several decades, and both the diagnosis and treatment of patients with CD has evolved since 2018. Table 1 of the guideline outlines all 35 recommendations for management of CD, which span diagnosis, endoscopy, medical management (broken down by mild-to-moderately severe disease with a lower or higher risk for disease progression), fistulizing CD, when to refer to surgery, and postoperative care (according to low and high risk for postoperative recurrence). Table 2 of the guideline offers 59 'key concepts' covering clinical features, natural history, intestinal malignancy, diagnosis, disease modifiers, and medical and surgery management. In making a diagnosis, it's important to consider clinical presentation as well as endoscopic, radiologic, histologic, and pathologic findings, the authors said. They advise using fecal calprotectin (cutoff > 50-100 ug/g) to differentiate inflammatory from noninflammatory disease of the colon. Routine endoscopic surveillance for colorectal cancer in patients with Crohn's colitis is also recommended. Medical Treatment 'Medical treatment of CD is usually categorized into induction and maintenance therapy,' the authors wrote. Treatment regimens are usually chosen with 'a goal to achieve clinical and biomarker response within 12 weeks of treatment initiation followed by durable steroid-free control of disease activity including both clinical and endoscopic remission.' However, objective outcomes like endoscopic improvements have only recently been added to clinical trials, they noted. The authors stressed that early initiation of advanced therapy is 'key' for optimal outcomes and that failure of conventional therapy before initiation of advanced therapy is not required. For mild to moderately severe disease (with a lower risk for progression), oral mesalamine is not recommended for induction or maintenance; ileal release budesonide is recommended for induction but not maintenance; and sulfasalazine should be considered only for those with symptomatic mild colonic CD. For moderate to severe CD (with a higher risk for progression) there are 17 recommendations, including: Oral corticosteroids are recommended for short-term induction of remission but not maintenance. Azathioprine and 6-mercaptopurine are not recommended for induction of remission but are recommended for maintenance of remission, with thiopurine methyltransferase testing done before initiation. However, given the adverse effect profile of thiopurine monotherapy, newer safer agents for maintenance should be considered. Methotrexate for maintenance of steroid-free remission is suggested. Anti-TNF agents (IV infliximab; SC adalimumab or certolizumab pegol) are recommended for induction and maintenance; SC infliximab for maintenance only; TB and hepatitis B status should be checked before treatment. Vedolizumab, ustekinumab, upadacitinib, guselkumab, mirikizumab, and risankizumab are all options for induction and maintenance. For fistulizing CD, infliximab, adalimumab, antibiotics, upadacitinib, vedolizumab or ustekinumab are recommended options for induction of remission. Referral to Surgery In terms of when to refer to surgery, patients with an intra-abdominal abscess > 2 cm should be treated with drainage and antibiotics. Patients with symptomatic fibrostenotic strictures or abdominal abscesses should be considered for surgery, the authors advised. In patients with surgically induced remission, colonoscopy 6-12 months after surgery is recommended to assess for early recurrent CD. Patients with a low post-op risk of recurrence can be observed. Patients with a high risk of post-op recurrence should consider starting advanced therapy shortly after resection with an anti-TNF agent or vedolizumab. High-risk patients include active smokers, those with penetrating disease and prior CD resections. The guidance also emphasizes the importance of addressing disease modifiers including NSAID use, cigarette smoking, diet, and management of stress, depression, and anxiety.
